524322
KABRADG
Start SIP
Invest Now
Start SIP in KABRADG
Performance
- Low
- ₹27
- High
- ₹28
- 52 Week Low
- ₹10
- 52 Week High
- ₹33
- Open Price₹28
- Previous Close₹28
- Volume35,765
- 50 DMA₹26.95
- 100 DMA₹23.97
- 200 DMA₹19.44
Investment Returns
- Over 1 Month + 3.64%
- Over 3 Month + 41.04%
- Over 6 Month + 30.99%
- Over 1 Year + 177.73%
Smart Investing Starts Here Start SIP with Kabra Drugs for Steady Growth!
Kabra Drugs Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- 55.5
- PEG Ratio
- 0.3
- Market Cap Cr
- 66
- P/B Ratio
- 2.5
- Average True Range
- 1.68
- EPS
- -
- Dividend Yield
- 0
- MACD Signal
- 0.54
- RSI
- 46.74
- MFI
- 62.26
Kabra Drugs Financials
Kabra Drugs Technicals
EMA & SMA
Current Price
₹27.94
+
0.07
(0.25%)
- Bearish Moving Average 9
- Bullish Moving Average 7
- 20 Day
- ₹28.56
- 50 Day
- ₹26.95
- 100 Day
- ₹23.97
- 200 Day
- ₹19.44
Resistance and Support
27.71
- R3 29.66
- R2 28.99
- R1 28.38
- S1 27.10
- S2 26.43
- S3 25.82
Kabra Drugs Corporate Actions - Bonus, Splits, Dividends
| Date | Purpose | Remarks |
|---|---|---|
| 2025-11-28 | Others | Inter alia, To sign an agreement with MR FRANCHISE to appoint around 200 channel partner throughout the Country for expansion. |
| 2025-11-13 | Quarterly Results | |
| 2025-10-08 | Others | Inter-aliam to consider 1.Approve the final draft of the Share Purchase Agreement (SPA) in relation to the acquisition of AMR PHARMA INDIA PRIVATE LIMITED. 2. Other business matters. |
| 2025-09-02 | Others | Inter-alia, to consider 1. Directors Report and Corporate Governance Report for the financial year 2024 -25. 2. Draft Notice calling the AGM. 3. Other business matters. |
| 2025-08-14 | Quarterly Results |
Kabra Drugs F&O
About Kabra Drugs
- NSE Symbol
- KABRADG
- BSE Symbol
- 524322
- Managing Director
- Mr. N Aravind
- ISIN
- INE323K01017
Similar Stocks to Kabra Drugs
Kabra Drugs FAQs
Kabra Drugs share price is ₹27 As on 18 January, 2026 | 08:20
The Market Cap of Kabra Drugs is ₹66.2 Cr As on 18 January, 2026 | 08:20
The P/E ratio of Kabra Drugs is 55.5 As on 18 January, 2026 | 08:20
The PB ratio of Kabra Drugs is 2.5 As on 18 January, 2026 | 08:20
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.